Associated Disease Details
| Disease ID: | I17 |
| DO ID: | 1596 |
| Disease Name: | Mental depression |
| Definition: | Mental depression |
| Synonyms: | depression |
| Class: | disease of mental health/ cognitive disorder/ mood disorder |
| Related Drugs: | S-adenosyl-L-methionine |
| Mechanism: | Growing evidence suggests a positive association between metabolic syndrome and certain mental health problems (e.g., depression, anxiety, and chronic stress). Given the strong overlap between metabolic syndrome and NAFLD, and the common underlying mechanisms that link the two conditions, it is probable that potentially bidirectional associations are also present between NAFLD and mental health comorbidity. Recently, a significant association between these hepatic diseases and different central nervous system (CNS) disorders has been observed in an increasing number of patients. NAFLD-related CNS dysfunctions include cognitive impairment, hippocampal-dependent memory impairment, and mood imbalances (in particular, depression and anxiety). This review aims at summarizing the main correlations observed between NAFLD development and these CNS dysfunctions, focusing on the studies investigating the mechanism(s) involved in this association. Growing evidences point at cerebrovascular alteration, neuroinflammation, and brain insulin resistance as NAFLD/NASH-related CNS manifestations. |
| Reference (PMIDs): | 34829926; 32708059 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D092 | Curcumin | Chemical drug | DB11672 | PPARG; COX inhibitor | Anticancer agent; NSAID | Under clinical trials | Details |
| D192 | JKB-121 | Chemical drug | DB06230 | TLR4 antagonist | Anti-inflammatory | Under clinical trials | Details |
| D203 | Levothyroxine | Chemical drug | DB00451 | THRA agonist; THRB agonist | Anti-fibrosis | Under clinical trials | Details |
| D305 | Rimonabant | Chemical drug | DB06155 | CNR1 antagonist | Antialcoholic drug; CNS drug | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0036 | DB00120 | approved; investigational; nutraceutical | small molecule | Phenylalanine | Indication associated | Details |
| R0037 | DB00121 | approved; investigational; nutraceutical | small molecule | Biotin | Target associated | Details |
| R0052 | DB00150 | approved; nutraceutical; withdrawn | small molecule | Tryptophan | Indication associated | Details |
| R0055 | DB00157 | approved; nutraceutical | small molecule | NADH | Target associated | Details |
| R0063 | DB00176 | approved; investigational | small molecule | Fluvoxamine | Indication associated | Details |
| R0068 | DB00182 | approved; illicit; investigational | small molecule | Amphetamine | Indication associated | Details |
| R0071 | DB00193 | approved; investigational | small molecule | Tramadol | Therapeutic strategy associated | Details |
| R0074 | DB00201 | approved | small molecule | Caffeine | Indication associated | Details |
| R0082 | DB00215 | approved | small molecule | Citalopram | Indication associated | Details |
| R0091 | DB00234 | approved; experimental | small molecule | Reboxetine | Indication associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00164 | 35203659 | Biomedicines | Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. | Details |
| A00489 | 35064417 | Qual Life Res | The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States. | Details |
| A00516 | 35054924 | Int J Mol Sci | GLP-1a: Going beyond Traditional Use. | Details |
| A00719 | 34990473 | PLoS One | Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism. | Details |
| A00730 | 34986375 | J Affect Disord | Association between nonalcoholic fatty liver disease and depression: A systematic review and meta-analysis of observational studies. | Details |
| A00941 | 34923459 | Wiad Lek | THE EFFECTIVENESS OF COMPLEX THERAPY WITH THE INCLUSION OF THE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | Details |
| A00957 | 34919585 | PLoS One | Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action. | Details |
| A01161 | 34848360 | J Ethnopharmacol | Crocetin ameliorates non-alcoholic fatty liver disease by modulating mitochondrial dysfunction in L02 cells and zebrafish model. | Details |
| A01202 | 34829926 | Biomedicines | Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress. | Details |
| A01299 | 34797530 | Rheumatol Ther | Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. | Details |
| A01945 | 34557498 | Front Med (Lausanne) | Fecal Microbiota Transplantation as a Tool for Therapeutic Modulation of Non-gastrointestinal Disorders. | Details |
| A02122 | 34498413 | Pediatr Obes | Recent advances in the epidemiology of nonalcoholic fatty liver disease in children. | Details |
| A02511 | 34346124 | Cell Prolif | Curcumol inhibits ferritinophagy to restrain hepatocyte senescence through YAP/NCOA4 in non-alcoholic fatty liver disease. | Details |
| A02533 | 34338703 | Food Funct | Co-supplementation of camelina oil and a prebiotic is more effective for in improving cardiometabolic risk factors and mental health in patients with NAFLD: a randomized clinical trial. | Details |
| A02706 | 34277666 | Front Med (Lausanne) | Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease. | Details |
| A02725 | 34272900 | Int J Eat Disord | Binge-eating disorder is associated with an unfavorable body mass composition in patients with non-alcoholic fatty liver disease. | Details |
| A02856 | 34214585 | Eur J Pharmacol | The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial. | Details |
| A02931 | 34192792 | Horm Metab Res | Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic Syndrome. | Details |
| A02939 | 34190396 | J Cell Mol Med | LncRNA MAYA promotes iron overload and hepatocyte senescence through inhibition of YAP in non-alcoholic fatty liver disease. | Details |
| A03184 | 34096467 | Bioengineered | The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. | Details |